Ultrasonic interventional analgesia in pancreatic carcinoma with chemical destruction of celiac ganglion.
OBJECTIVE
To detect the therapeutic effects of chemical destruction of celiac ganglion in patients with pancreatic carcinoma with intractable pain.


METHODS
Ninety-seven cases with advanced pancreatic carcinoma received chemical destruction of celiac ganglion-5 mL pure alcohol injection around celiac artery under ultrasonic guidance. The changes of visual analogue scale (VAS), serum substance P (Sub P), beta-endopeptide (beta-EP) and T-lymphocyte subtypes level were compared between pre- and post-therapy.


RESULTS
Successful rate of puncture was 98.7%, with one failure. No serious complications such as traumatic pancreatitis, pancreatic fistula, abdominal cavity hemorrhage or peritoneal infection occurred. VAS, serum Sub P and beta-EP level significantly changed after treatment (8.0+/-2.3 vs 4.6+/-2.1, 254.1+/-96.7 vs 182.4+/-77.6, 3.2+/-0.8 vs 8.8+/-2.1, P<0.01, P<0.05, P<0.01) with complete relief rate 54.2%, partial relief rate 21.9%, ineffective rate 12.5% and recurrent rate 10.7%. The T-lymphocyte subtypes level remarkably increased when compared with that of pre-therapy (46.7+/-3.7 vs 62.5+/-5.5, P<0.01).


CONCLUSIONS
Our study suggests that chemical destruction of celiac ganglion under ultrasonic guidance is highly safe, and can evidently relieve cancer pain and improve the cellular immunity in patients with advanced pancreatic carcinoma.
Wang
Tao
T
Department of The General Hospital of Chengdu Military Command Area, Chengdu, Tianhui Town, 610085, Sichuan Province, China. watopo@163.com
Tian
Fu-Zhou
FZ
Cai
Zhong-Hong
ZH
Li
Xu
X
Cheng
Tao
T
Shi
Li
L
Cheng
Qi
Q
D000328:Adult; D000368:Aged; D000698:Analgesia / Q000379:methods*; D017252:CD3 Complex / Q000502:physiology; D015704:CD4 Antigens / Q000276:immunology; D016827:CD8 Antigens / Q000502:physiology; D002277:Carcinoma / Q000150:complications*; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005728:Ganglia, Sympathetic / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D007109:Immunity / Q000502:physiology; D008297:Male; D008875:Middle Aged; D018847:Opioid Peptides / Q000097:blood; D010147:Pain Measurement; D010148:Intractable Pain / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy*; D010190:Pancreatic Neoplasms / Q000150:complications*; D013373:Substance P / Q000097:blood; D016176:T-Lymphocyte Subsets; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D018847:Opioid Peptides; D013373:Substance P; D000431:Ethanol